NCT02353832View on ClinicalTrials.gov

Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 6, 2014

Primary Completion Date

January 29, 2018

Study Completion Date

January 5, 2021

Conditions
Prostate Cancer
Interventions
DEVICE

Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)

Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02353832 - Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer | Biotech Hunter | Biotech Hunter